VBIV
$1.53
Vbi Vaccines Inc CS
($.06)
(3.77%)
VBIV
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.06)
Revenue:  $0.97 Mil
Monday
Feb 24
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when VBIV reports earnings?
Beat
Meet
Miss

Where is VBIV's stock price going from here?
Up
Flat
Down
Stock chart of VBIV
Analysts
Summary of analysts' recommendations for VBIV
Score
Grade
Pivots
Resistance
$1.69
$1.66
$1.59

$1.56

Support
$1.49
$1.46
$1.39
Tweet
Growth
Description
VBI Vaccines, Inc. is a biopharmaceutical company. It develops technologies which seek to expand vaccine protection during storage or shipment. The Company's eVLP vaccine platform allows for the design of enveloped (e) virus-like particle (VLP) vaccines that closely mimic the target virus. The company's second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI Vaccines, Inc., formerly known as Paulson Capital Corp., is headquartered in Cambridge, Massachusetts.